BioMarin (BMRN) Posts Strong Q2 Growth, Advances Rare Disease Research

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the best growth stocks to buy according to analysts. On August 4, BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) released its Q2 2025 earnings. The company reported a 16% year-over-year increase in revenue, which stood at $825 million for the quarter. The company also reported a significant rise in EPS, a stark improvement from the EPS of $0.55 per share it reported for the same quarter during the previous year. It reported an EPS of $1.23, versus $0.861, a comprehensive beat. BioMarin raised its full-year guidance for total revenues and operating margin.

BioMarin (BMRN) Posts Strong Q2 Growth, Advances Rare Disease Research

A pharmaceutical plant manufacturing a proprietary synthetic oral form of a C-type natriuretic peptide.

BioMarin reported that its revenue from VOXZOGO jumped 20% thanks to rising demand across international markets. Sales from its enzyme therapies also saw healthy growth, increasing 15% year-over-year. The recent acquisition of Inozyme brought in a new enzyme replacement therapy candidate, further strengthening BioMarin’s rare disease portfolio.

The company continues to make huge strides in rare disease research. BioMarin is making progress in the diagnosis of hypochondroplasia, a rare genetic disorder that affects bone growth and leads to short stature. The company is currently focusing on reclassifying genetic “variants of uncertain significance”, a common obstacle in genetic testing that leaves doctors and patients without clear answers.

READ NEXT: 10 Best Military Tech Stocks to Buy Now and 10 High Growth Stocks Outside Tech Analysts Are Bullish On.